The primary objective of this study is to determine whether lansoprazole, administered
intravenously, can protect patients undergoing cardiac surgery from the development of and/or
progression of previously undetected acid/peptic disorders (erosive esophagitis, gastric
ulcer, duodenal ulcer, diffuse gastritis, duodenitis) as measured by the Lanza score and LA
classification for esophageal injury.
The secondary objectives of this study are:
1. To determine if intravenous lansoprazole protects against the development of clinically
important gastrointestinal bleeding in this population (overt bleeding or requiring
blood transfusion).
2. To determine if intravenous lansoprazole maintains the intragastric pH above that for
placebo throughout the study period.